Background Cardiovascular events are the leading cause of death in end stage renal
disease (ESRD), but traditional markers of dyslipidemia are not clearly associated with …

Background Proprotein convertase subtilisin/kexin type 9 (PCSK9), a factor accelerating the
degradation of LDL receptors, was associated with a gender‐dependent risk for …

Background Cardiovascular (CV) disease is the leading cause of mortality in patients with
end-stage kidney disease (ESKD). The aim of the present study was to determine whether …

Background Chronic kidney disease is a risk factor for premature development of coronary
atherosclerosis and mortality. A high level of proprotein convertase subtilisin/kexin type 9 …

Methods A cross-sectional study was conducted between August 2016 and July 2020 in six
hemodialysis centers in the city of Kinshasa, Democratic Republic of the Congo. Serum …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising new target for the
prevention of cardiovascular (CV) events. However, the clinical significance of circulating …

Cardiovascular disease (CVD) including coronary artery disease, heart failure, arrhythmias
and sudden cardiac death has a major influence on morbidity and mortality and is the …

Abstract Background Chronic Kidney Disease (CKD) and, specifically, diabetic kidney
disease (DKD)+, is among the fastest increasing causes of death worldwide. A better …

Background: Elevated levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) have
been reported to be related to dyslipidemia, including patients with kidney dysfunction …

Purpose Chronic kidney disease (CKD) is accompanied by a number of secondary
metabolic dysregulations, such as lipid abnormalities, presenting with unique …